Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egrifta Post-marketing Study On Diabetic Retinopathy Will Include CV Outcomes

Executive Summary

FDA’s decision to require a post-approval clinical trial evaluating the cardiovascular effects of Theratechnologies’ HIV lipodystrophy drug Egrifta shows the agency has overcome concerns – both its own and those of its advisory committee – that such a study could not be feasibly and ethically conducted.
Advertisement

Related Content

Egrifta Approval Suggests Evolution In FDA Thinking On Role Of REMS
Egrifta Approval Suggests Evolution In FDA Thinking On Role Of REMS
Delayed Egrifta Approval Brings Clean Label, No REMS For Theratechnologies
Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation
Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation
The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS052855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel